ExQor's CNS platform is able to target specific regions in the brain with large molecule drugs that solve unmet medical needs.
ExQor’s multi-patented CNS drug platform non-invasively crosses an intact blood brain barrier. The blood brain barrier (BBB) protects the brain. But the same barrier also prevents almost all drug treatments from gaining access to the brain
The barrier thus severely limits the creation and delivery of drugs to treat CNS diseases and disorders. The use of large molecule biologics is essentially barred.
ExQor's ability to deliver biologics to brain opens up new approaches to treating CNS disorders that so far have been intractable. Our program pipeline currently includes developing treatments for:
Alzheimer’s
HIV-1 associated neurocognitive disorders (HAND)
METH addiction
ExQor's patented bio-nanotechnology platform non-invasively delivers large molecule biologics across the blood brain barrier in therapeutically effective amounts and in up to 400X greater concentrations than other delivery methods, including invasive. The biologics are also targeted to specific brain regions in need of treatment, such as the hippocampus, striatum, and to other individual regions. ExQor will be producing a drug that has been shown effective in multiple preclinical studies for treating cognitive decline by regenerating relevant brain tissue and preventing further damage.
Long Haul COVID
In August 2022, 16 million working age Americans reported having Long COVID. (US Census, National Center for Health Statistics) About 60% of those with Long COVID report problems with remembering and concentrating. (Federal Reserve, 2022) Some studies show that susceptibility, hospitalization, and severity of COVID could increase the risk of Alzheimer's disease. Other studies indicate there appears to be a significant overlap between Alzheimer's and COVID. These and other published studies could indicate that Alzheimer's would become a significant factor in Long COVID, affecting millions, and in some instances, Alzheimer's could appear as soon as one year post infection.
ExQor's Alzheimer's drug might also be effective in reversing cognitive problems in subjects with Long COVID. And whereas Long COVID may follow similar pathways as Alzheimer's, ExQor also might be able to treat Long COVID subjects who are experiencing early stage Alzheimer's.
An ExQor treatment for Long COVID could also have significant impact in mitigating strains on US national resources, e.g., the Office for Civil Rights of the Department of Health and Human Services and the Civil Rights Division of the Department of Justice have issued a guidance that states, "Long COVID is a physical or mental impairment under the Americans with Disabilities Act (ADA), Section 504, and Section 1557."